Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Nov 4:15:100343.
doi: 10.1016/j.jpi.2023.100343. eCollection 2024 Dec.

Computational pathology in the identification of HER2-low breast cancer: Opportunities and challenges

Marie Brevet  1 , Zaibo Li  2 , Anil Parwani  2
Affiliations
Review

Computational pathology in the identification of HER2-low breast cancer: Opportunities and challenges

Marie Brevet et al. J Pathol Inform. .

Abstract

For the past 2 decades, pathologists have been accustomed to reporting the HER2 status of breast cancer as either positive or negative, based on HER2 IHC. Today, however, there is a clinical imperative to employ a 3-tier approach to interpreting HER2 IHC that can also identify tumours categorised as HER2-low. Meeting this need for a finer degree of discrimination may be challenging, and in this article, we consider the potential for the integration of computational approaches to support pathologists in achieving accurate and reproducible HER2 IHC scoring as well as outlining some of the practicalities involved.

Keywords: HER2; HER2-low; breast carcinoma; computational pathology; digital pathology; immunohistochemistry.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

    1. Atallah N.M., Toss M.S., Green A.R., Mongan N.P., Ball G., Rakha E.A. Refining the definition of HER2-low class in invasive breast cancer. Histopathology. 2022;81:770–785. doi: 10.1111/his.14780. - DOI - PMC - PubMed
    1. Tarantino P., Hamilton E., Tolaney S.M., et al. HER2-low breast cancer: pathological and clinical landscape. J Clin Oncol. 2020;38:1951–1962. doi: 10.1200/JCO.19.02488. - DOI - PubMed
    1. Rakha E.A., Tan P.H., Quinn C., et al. UK recommendations for HER2 assessment in breast cancer: an update. J Clin Pathol. 2023;76:217–227. doi: 10.1136/jcp-2022-208632. - DOI - PubMed
    1. Wolff A.C., Hammond M.E.H., Allison K.H., et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. J Clin Oncol. 2018;36:2105–2122. doi: 10.1200/JCO.2018.77.8738. - DOI - PubMed
    1. Vandenberghe M.E., Scott M.L., Scorer P.W., Söderberg M., Balcerzak D., Barker C. Relevance of deep learning to facilitate the diagnosis of HER2 status in breast cancer. Sci Rep. 2017;7:45938. doi: 10.1038/srep45938. - DOI - PMC - PubMed